Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Rural-urban divide for cancer in Medicare: An analysis of utilization and outcomes in fee-for-service Medicare in 2023.

The rural cancer population covered by TM experienced significantly higher annual all-cause mortality and lower hospice use in 2023, and spending per beneficiary, comorbidity burdens, and common cancer prevalence were comparable between beneficiaries accessing care in urban versus rural settings in TM.

T. Olsen, Robin K. Yabroff, E. Sharon · 0 citations
Open access Sep 2026

Validating LLM judges for automated oversight of patient communication

A stakeholder-informed seven-criterion evaluation rubric spanning safety, reliability, and communication quality is developed and benchmarked 19 LLM judges across multiple implementation strategies, supporting LLM judges for scalable patient communication oversight while demonstrating the need for recalibration to pati...

Zi-Du Xu, Johnathan Zeng, Shuang Zhou et al. · 0 citations
Aug 2026

Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

BACKGROUND Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...

F. Pecci, Xinan Wang, Valentina Santo et al. · 0 citations
Review Open access Sep 2026

The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact

This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.

Joud Hajjar, B. Stephen, A. Aaroe et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.